Compare Illumina, Inc. (ILMN) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Schwab US Dividend Equity ETF — how do they compare? Illumina, Inc. trades at $268.9 (market cap $39.95B), while Schwab US Dividend Equity ETF trades at $32.99 (market cap $110.56B). The key difference: Schwab US Dividend Equity ETF is far larger — about 2.8× Illumina, Inc.'s market cap, and Illumina, Inc. is trading nearer its 52-week high, Schwab US Dividend Equity ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Schwab US Dividend Equity ETF for 62 Days on average.
| ILMN | SCHD | |
|---|---|---|
Market Cap | $39.95B | $110.56B |
Volume | 3,169,503 | 23,539,168 |
Sector | Health | Broad Market / Factor |
52-Week High | $293.69 | $35.21 |
52-Week Low | $91.00 | $26.44 |
Typical Hold Time | 83 Days | 62 Days |
Enterprise Value | $41.31B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
SCHD trades at $32.65, down 0.61% with a bearish technical signal from moving averages. Recent news highlights its strong 2026 performance against the S&P 500 and a recent dividend declaration. The ETF's defensive dividend strategy faces pressure from rising interest rates, contributing to recent price weakness from August highs near $35.
The outlook balances income growth potential against interest rate sensitivity. Near-term support at $32 provides a key level to watch, while the dividend-focused approach offers stability for long-term investors despite current technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
